查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1352919

全球慢性阻塞性肺病 (COPD) 治療市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日期: | 出版商: Value Market Research | 英文 168 Pages | 商品交期: 最快1-2個工作天內

價格

全球慢性阻塞性肺病（COPD）治療市場的需求預計將從2022年的230.2億美元增加到2030年的近384.4億美元，2023-2030年研究期間的複合年成長率為6.62%。

肺部發炎會導致慢性阻塞性肺病（COPD），進而阻礙肺部氣流。這是一種慢性疾病，症狀包括喘息、產生黏液和呼吸困難。肺部疾病包括難治性氣喘、肺氣腫和慢性支氣管炎。慢性阻塞性肺病主要是由吸菸、空氣污染、二手菸、α-1缺乏相關肺氣腫（慢性阻塞性肺病的一種罕見形式）和其他因素引起的。在某些情況下可以避免併發症，在其他情況下可以減少疾病進展。這些措施可能包括戒菸、依照指示服用處方藥，以及接種流感、肺炎等感染疫苗，以預防相關的併發症。

市場動態：

由於三聯療法和數位吸入器選項的日益普及，慢性阻塞性肺病（COPD）治療市場的市場參與者預計在研究期間需求將會增加。慢性阻塞性肺病的危險因子不斷增加，使得這種疾病相當普遍，從而迫使政府和醫療機構提供更好的治療。此外，公眾對慢性阻塞性肺病預防的認知有所提高，預計將推動該市場的發展。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球慢性阻塞性肺病 (COPD) 治療市場的各個細分市場進行了包容性評估。慢性阻塞性肺病 (COPD) 治療產業的成長和趨勢為本研究提供了整體方法。

區域分析：

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的慢性阻塞性肺病（COPD）治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。慢性阻塞性肺病（COPD）治療市場的主要參與者包括Almirall、阿斯特捷利康、勃林格殷格翰國際有限公司、CHIESI Farmaceutici SpA、F. Hoffmann-La Roche Ltd.、葛蘭素史克公司、Kyowa Hakko Kirin、Mylan NV、諾華公司、 Orion Corporation、賽諾菲、Sunovion Pharmaceuticals Inc. （住友大日本製藥有限公司）、Teva Pharmaceutical Industries Ltd.、Theravance Biopharma、Verona Pharmaceuticals。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第一章：前言

  • 報告說明
    • 客觀的
    • 目標受眾
    • 獨特的銷售主張 (USP) 和產品
  • 研究範圍
  • 研究方法論
    • 市場研究過程
    • 市場研究方法論

第 2 章：執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章：慢性阻塞性肺病 (COPD) 治療 - 產業分析

  • 簡介 - 市場動態
  • 市場促進因素
  • 市場限制
  • 機會
  • 產業動態
  • 波特五力分析
  • 市場吸引力分析
    • 按藥品類別分類的市場吸引力分析
    • 按類型分類的市場吸引力分析
    • 按分銷管道分類的市場吸引力分析
    • 市場吸引力分析：按地區

第 4 章：價值鏈分析

  • 價值鏈分析
  • 原料分析
    • 原料清單
    • 原料廠商清單
    • 主要原物料價格走勢
  • 潛在買家名單
  • 行銷管道
    • 直效行銷
    • 間接行銷
    • 行銷通路發展趨勢

第 5 章：COVID-19 爆發的影響分析

第 6 章：全球慢性阻塞性肺病 (COPD) 治療市場分析：按藥物類別

  • 按藥物類別概述
  • 歷史和預測數據
  • 按藥物類別分析
  • 聯合療法
  • 支氣管擴張劑
  • 皮質類固醇
  • 4 型磷酸二酯酶抑制劑
  • 黏液動力學
  • 其他

第 7 章：全球慢性阻塞性肺病 (COPD) 治療市場分析：按類型

  • 按類型概述
  • 歷史和預測數據
  • 按類型分析
  • 慢性支氣管炎
  • 氣腫

第 8 章：全球慢性阻塞性肺病 (COPD) 治療市場銷售分析：按分銷管道

  • 按分銷管道分類的概覽
  • 歷史和預測數據
  • 按分銷管道分析
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 9 章：全球慢性阻塞性肺病 (COPD) 治療市場銷售分析：按地理位置

  • 區域展望銷售分析
  • 簡介 銷售分析
  • 北美銷售分析
    • 概述、歷史和預測銷售分析
    • 北美按細分市場銷售分析
    • 北美按國家銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概述、歷史和預測銷售分析
    • 歐洲按細分市場銷售分析
    • 歐洲按國家銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 義大利銷售分析
    • 俄羅斯銷售分析
    • 歐洲其他地區銷售分析
  • 亞太地區銷售分析
    • 概述、歷史和預測銷售分析
    • 亞太地區按細分市場銷售分析
    • 亞太地區國家/地區銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳洲銷售分析
    • 亞太地區其他地區銷售分析
  • 拉丁美洲銷售分析
    • 概述、歷史和預測銷售分析
    • 拉丁美洲按細分市場銷售分析
    • 拉丁美洲按國家銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利銷售分析
    • 拉丁美洲其他地區銷售分析
  • 中東和非洲銷售分析
    • 概述、歷史和預測銷售分析
    • 中東和非洲按細分市場銷售分析
    • 中東和非洲國家銷售分析
    • 沙烏地阿拉伯銷售分析
    • 阿拉伯聯合大公國銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 中東其他地區和非洲銷售分析

第 10 章：慢性阻塞性肺病 (COPD) 治療公司的競爭格局

  • 慢性阻塞性肺病（COPD）治療市場競爭
  • 夥伴關係/協作/協議
  • 併購
  • 新產品發布
  • 其他發展

第 11 章：公司簡介

  • 十大公司股票分析
  • 市場集中度
  • Almirall
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • AstraZeneca
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Boehringer Ingelheim International GmbH
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • CHIESI Farmaceutici SpA
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • F. Hoffmann-La Roche Ltd.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • GlaxoSmithKline plc
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Kyowa Hakko Kirin
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Mylan NV
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Novartis AG
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Orion Corporation
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Sanofi
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Sunovion PharmaceuticalsInc. (Sumitomo Dainippon Pharma Co. Ltd.)
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Teva Pharmaceutical Industries Ltd.
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Theravance Biopharma
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展
  • Verona Pharmaceuticals
    • 公司簡介
    • 公司收入
    • 產品
    • 最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

Product Code: VMR11218849

The global demand for Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is presumed to reach the market size of nearly USD 38.44 BN by 2030 from USD 23.02 BN in 2022 with a CAGR of 6.62% under the study period 2023 - 2030.

Inflammation of the lungs contributes to chronic obstructive pulmonary disease (COPD), which blocks airflow from the lungs. It is a chronic ailment with symptoms that include wheezing, mucous production, and trouble breathing. The lung condition comprises refractory asthma, emphysema, and chronic bronchitis. COPD is mostly brought on by smoking, air pollution, secondhand smoke, alpha-1 deficiency-related emphysema (a rare form of COPD), and other factors. Complications can be avoided in some situations, and illness progression can be reduced in others. These may include giving up smoking, taking prescribed medications as directed, and being vaccinated against infections like the flu, pneumonia, and others to prevent associated co-morbidities.

MARKET DYNAMICS:

Due to the growing popularity of triple therapy treatment options and digital inhaler options, market players within the chronic obstructive pulmonary disease (COPD) treatment market is projected to experience an increase in demand during the study period. Increasing risk factors for developing chronic obstructive pulmonary disease have made the condition rather common, thus forcing government and healthcare institutions to provide better treatment. Additionally, there has been an increase in public awareness of COPD prevention, which is anticipated to boost this market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of chronic obstructive pulmonary disease (copd) treatment. The growth and trends of chronic obstructive pulmonary disease (copd) treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the chronic obstructive pulmonary disease (copd) treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

  • Combination Therapy
  • Bronchodilators
  • Corticosteroids
  • Phosphodiesterase Type 4 Inhibitor
  • Mucokinetics
  • Others

By Type

  • Chronic Bronchitis
  • Emphysema

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Chronic Obstructive Pulmonary Disease (COPD) Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the chronic obstructive pulmonary disease (copd) treatment market include Almirall, AstraZeneca, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Kyowa Hakko Kirin, Mylan N.V., Novartis AG, Orion Corporation, Sanofi, Sunovion PharmaceuticalsInc. (Sumitomo Dainippon Pharma Co., Ltd.), Teva Pharmaceutical Industries Ltd., Theravance Biopharma, Verona Pharmaceuticals. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Class
    • 3.7.2 Market Attractiveness Analysis By Type
    • 3.7.3 Market Attractiveness Analysis By Distribution Channel
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET ANALYSIS BY DRUG CLASS

  • 6.1 Overview by Drug Class
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Drug Class
  • 6.4 Combination Therapy Historic and Forecast Sales by Regions
  • 6.5 Bronchodilators Historic and Forecast Sales by Regions
  • 6.6 Corticosteroids Historic and Forecast Sales by Regions
  • 6.7 Phosphodiesterase Type 4 Inhibitor Historic and Forecast Sales by Regions
  • 6.8 Mucokinetics Historic and Forecast Sales by Regions
  • 6.9 Others Historic and Forecast Sales by Regions

7 . GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET ANALYSIS BY TYPE

  • 7.1 Overview by Type
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Type
  • 7.4 Chronic Bronchitis Historic and Forecast Sales by Regions
  • 7.5 Emphysema Historic and Forecast Sales by Regions

8 . GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET SALES ANALYSIS BY DISTRIBUTION CHANNEL

  • 8.1 Overview by Distribution Channel
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by Distribution Channel
  • 8.4 Hospital Pharmacies Historic and Forecast Sales by Regions
  • 8.5 Retail Pharmacies Historic and Forecast Sales by Regions
  • 8.6 Online Pharmacies Historic and Forecast Sales by Regions

9 . GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT MARKET SALES ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook Sales Analysis
  • 9.2. Introduction Sales Analysis
  • 9.3. North America Sales Analysis
    • 9.3.1. Overview, Historic and Forecast Sales Analysis
    • 9.3.2. North America By Segment Sales Analysis
    • 9.3.3. North America By Country Sales Analysis
    • 9.3.4. United State Sales Analysis
    • 9.3.5. Canada Sales Analysis
    • 9.3.6. Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1. Overview, Historic and Forecast Sales Analysis
    • 9.4.2. Europe by Segment Sales Analysis
    • 9.4.3. Europe by Country Sales Analysis
    • 9.4.4. United Kingdom Sales Analysis
    • 9.4.5. France Sales Analysis
    • 9.4.6. Germany Sales Analysis
    • 9.4.7. Italy Sales Analysis
    • 9.4.8. Russia Sales Analysis
    • 9.4.9. Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1. Overview, Historic and Forecast Sales Analysis
    • 9.5.2. Asia Pacific by Segment Sales Analysis
    • 9.5.3. Asia Pacific by Country Sales Analysis
    • 9.5.4. China Sales Analysis
    • 9.5.5. India Sales Analysis
    • 9.5.6. Japan Sales Analysis
    • 9.5.7. South Korea Sales Analysis
    • 9.5.8. Australia Sales Analysis
    • 9.5.9. Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1. Overview, Historic and Forecast Sales Analysis
    • 9.6.2. Latin America by Segment Sales Analysis
    • 9.6.3. Latin America by Country Sales Analysis
    • 9.6.4. Brazil Sales Analysis
    • 9.6.5. Argentina Sales Analysis
    • 9.6.6. Peru Sales Analysis
    • 9.6.7. Chile Sales Analysis
    • 9.6.8. Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1. Overview, Historic and Forecast Sales Analysis
    • 9.7.2. Middle East & Africa by Segment Sales Analysis
    • 9.7.3. Middle East & Africa by Country Sales Analysis
    • 9.7.4. Saudi Arabia Sales Analysis
    • 9.7.5. UAE Sales Analysis
    • 9.7.6. Israel Sales Analysis
    • 9.7.7. South Africa Sales Analysis
    • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT COMPANIES

  • 10.1. Chronic Obstructive Pulmonary Disease (Copd) Treatment Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11 . COMPANY PROFILES OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT INDUSTRY

  • 11.1. Top 10 Company Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Almirall
    • 11.3.1. Company Overview
    • 11.3.2. Company Revenue
    • 11.3.3. Products
    • 11.3.4. Recent Developments
  • 11.4. AstraZeneca
    • 11.4.1. Company Overview
    • 11.4.2. Company Revenue
    • 11.4.3. Products
    • 11.4.4. Recent Developments
  • 11.5. Boehringer Ingelheim International GmbH
    • 11.5.1. Company Overview
    • 11.5.2. Company Revenue
    • 11.5.3. Products
    • 11.5.4. Recent Developments
  • 11.6. CHIESI Farmaceutici S.p.A.
    • 11.6.1. Company Overview
    • 11.6.2. Company Revenue
    • 11.6.3. Products
    • 11.6.4. Recent Developments
  • 11.7. F. Hoffmann-La Roche Ltd.
    • 11.7.1. Company Overview
    • 11.7.2. Company Revenue
    • 11.7.3. Products
    • 11.7.4. Recent Developments
  • 11.8. GlaxoSmithKline plc
    • 11.8.1. Company Overview
    • 11.8.2. Company Revenue
    • 11.8.3. Products
    • 11.8.4. Recent Developments
  • 11.9. Kyowa Hakko Kirin
    • 11.9.1. Company Overview
    • 11.9.2. Company Revenue
    • 11.9.3. Products
    • 11.9.4. Recent Developments
  • 11.10. Mylan N.V.
    • 11.10.1. Company Overview
    • 11.10.2. Company Revenue
    • 11.10.3. Products
    • 11.10.4. Recent Developments
  • 11.11. Novartis AG
    • 11.11.1. Company Overview
    • 11.11.2. Company Revenue
    • 11.11.3. Products
    • 11.11.4. Recent Developments
  • 11.12. Orion Corporation
    • 11.12.1. Company Overview
    • 11.12.2. Company Revenue
    • 11.12.3. Products
    • 11.12.4. Recent Developments
  • 11.13. Sanofi
    • 11.13.1. Company Overview
    • 11.13.2. Company Revenue
    • 11.13.3. Products
    • 11.13.4. Recent Developments
  • 11.14. Sunovion PharmaceuticalsInc. (Sumitomo Dainippon Pharma Co. Ltd.)
    • 11.14.1. Company Overview
    • 11.14.2. Company Revenue
    • 11.14.3. Products
    • 11.14.4. Recent Developments
  • 11.15. Teva Pharmaceutical Industries Ltd.
    • 11.15.1. Company Overview
    • 11.15.2. Company Revenue
    • 11.15.3. Products
    • 11.15.4. Recent Developments
  • 11.16. Theravance Biopharma
    • 11.16.1. Company Overview
    • 11.16.2. Company Revenue
    • 11.16.3. Products
    • 11.16.4. Recent Developments
  • 11.17. Verona Pharmaceuticals
    • 11.17.1. Company Overview
    • 11.17.2. Company Revenue
    • 11.17.3. Products
    • 11.17.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Drug Class (USD MN)
  • Combination Therapy Market Sales by Geography (USD MN)
  • Bronchodilators Market Sales by Geography (USD MN)
  • Corticosteroids Market Sales by Geography (USD MN)
  • Phosphodiesterase Type 4 Inhibitor Market Sales by Geography (USD MN)
  • Mucokinetics Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis Market by Type (USD MN)
  • Chronic Bronchitis Market Sales by Geography (USD MN)
  • Emphysema Market Sales by Geography (USD MN)
  • Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Online Pharmacies Market Sales by Geography (USD MN)
  • Global Chronic Obstructive Pulmonary Disease (Copd) Treatment Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Chronic Obstructive Pulmonary Disease (Copd) Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Chronic Obstructive Pulmonary Disease (Copd) Treatment Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Drug Class
  • Market Attractiveness Analysis by Type
  • Market Attractiveness Analysis by Distribution Channel
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Drug Class (USD MN)
  • Combination Therapy Market Sales by Geography (USD MN)
  • Bronchodilators Market Sales by Geography (USD MN)
  • Corticosteroids Market Sales by Geography (USD MN)
  • Phosphodiesterase Type 4 Inhibitor Market Sales by Geography (USD MN)
  • Mucokinetics Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Type (USD MN)
  • Chronic Bronchitis Market Sales by Geography (USD MN)
  • Emphysema Market Sales by Geography (USD MN)
  • Global Market Analysis by Distribution Channel (USD MN)
  • Hospital Pharmacies Market Sales by Geography (USD MN)
  • Retail Pharmacies Market Sales by Geography (USD MN)
  • Online Pharmacies Market Sales by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Top Company Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.